| Name | Title | Contact Details |
|---|
Modis Therapeutics is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with high unmet medical need.
Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin`s lymphoma, acute myeloid leukemia and multiple solid tumors by leveraging our proprietary NK cell engager (TriKE™) platform technology.
Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine.
Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease.
BioVex Inc is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.